Obeticholic acid in primary biliary cholangitis
- PMID: 27825634
- DOI: 10.1016/j.clinre.2016.09.006
Obeticholic acid in primary biliary cholangitis
Abstract
In a double-blind, randomized, placebo-controlled study including 217 patients with primary biliary cholangitis, the authors show that obeticholic acid (a potent farnesoid X agonist) administered with ursodeoxycholic acid or as monotherapy significantly decreases serum alkaline phosphatase and bilirubin when compared to placebo. Pruritus (and serious adverse effects) was observed more frequently in obeticholic acid-treated patients than in controls, in spite of a decrease in serum bile acid concentration. These results are encouraging, but more studies are needed on clinical efficacy and safety before obeticholic acid can be widely recommended.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.
Comment on
-
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840. N Engl J Med. 2016. PMID: 27532829 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
